Fig. 4

CARM1 regulates the antagonism between EZH2 and BAF155 at the promoters of EZH2/BAF155 target genes. a Parental control and CARM1 knockout A1847 cells were treated with 10 μM GSK126 or vehicle controls. mRNA expression of the indicated genes was determined by qRT-PCR. *P < 0.002 compared with parental controls. b–d Parental control and CARM1 knockout A1847 cells were treated with 10 μM GSK126 or vehicle DMSO controls. The cells were subjected to ChIP analysis using anti-EZH2 (b), anti-H3K27Me3 (c), or anti-BAF155 (d) antibodies. *P < 0.001 compared with IgG controls and ^#P < 0.001 compared with parental controls. e The indicated CARM1-low cells with or without ectopic CARM1 expression were subjected to ChIP analysis using an anti-EZH2 antibody or an isotype-matched IgG control. *P < 0.05 compared with vector controls. f The indicated CARM1-low cells with or without shBAF155 expression were subjected to ChIP analysis using an anti-BAF155 antibody or an isotype-matched IgG control. *P < 0.03 compared with shControls. g–i Parental control and CARM1 knockout A1847 cells were treated with 10 μM GSK126 or vehicle DMSO controls. The cells were subjected to ChIP analysis using anti-SNF5 (g), anti-BRG1 (h), or anti-RNA Pol II (i) antibodies. ChIP products were subjected to qPCR analysis using primers specific for the promoter regions of the human DAB2, DLC1, and NOXA genes. *P < 0.001 compared with IgG controls and ^#P < 0.001 compared with parental controls. j Model proposed for the molecular basis of the selectivity against CARM1 expression by EZH2 inhibition. Means of three independent experiments with SEM. P-values are from two-tailed t-test